These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Just a spoonful of metformin helps the medicine go down. Tzaridis T; Wechsler-Reya RJ J Clin Invest; 2024 Mar; 134(6):. PubMed ID: 38488006 [TBL] [Abstract][Full Text] [Related]
3. ALK2 inhibitors display beneficial effects in preclinical models of Carvalho D; Taylor KR; Olaciregui NG; Molinari V; Clarke M; Mackay A; Ruddle R; Henley A; Valenti M; Hayes A; Brandon AH; Eccles SA; Raynaud F; Boudhar A; Monje M; Popov S; Moore AS; Mora J; Cruz O; Vinci M; Brennan PE; Bullock AN; Carcaboso AM; Jones C Commun Biol; 2019; 2():156. PubMed ID: 31098401 [TBL] [Abstract][Full Text] [Related]
4. Fimepinostat Impairs NF-κB and PI3K/AKT Signaling and Enhances Gemcitabine Efficacy in H3.3K27M-Diffuse Intrinsic Pontine Glioma. Wang D; Yan K; Yu H; Li H; Zhou W; Hong Y; Guo S; Wang Y; Xu C; Pan C; Tang Y; Liu N; Wu W; Zhang L; Xi Q Cancer Res; 2024 Feb; 84(4):598-615. PubMed ID: 38095539 [TBL] [Abstract][Full Text] [Related]
5. Reversal of cancer gene expression identifies repurposed drugs for diffuse intrinsic pontine glioma. Zhao G; Newbury P; Ishi Y; Chekalin E; Zeng B; Glicksberg BS; Wen A; Paithankar S; Sasaki T; Suri A; Nazarian J; Pacold ME; Brat DJ; Nicolaides T; Chen B; Hashizume R Acta Neuropathol Commun; 2022 Oct; 10(1):150. PubMed ID: 36274161 [TBL] [Abstract][Full Text] [Related]
6. ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma. Jackson ER; Duchatel RJ; Staudt DE; Persson ML; Mannan A; Yadavilli S; Parackal S; Game S; Chong WC; Jayasekara WSN; Grand ML; Kearney PS; Douglas AM; Findlay IJ; Germon ZP; McEwen HP; Beitaki TS; Patabendige A; Skerrett-Byrne DA; Nixon B; Smith ND; Day B; Manoharan N; Nagabushan S; Hansford JR; Govender D; McCowage GB; Firestein R; Howlett M; Endersby R; Gottardo NG; Alvaro F; Waszak SM; Larsen MR; Colino-Sanguino Y; Valdes-Mora F; Rakotomalala A; Meignan S; Pasquier E; André N; Hulleman E; Eisenstat DD; Vitanza NA; Nazarian J; Koschmann C; Mueller S; Cain JE; Dun MD Cancer Res; 2023 May; ():OF1-OF17. PubMed ID: 37195023 [TBL] [Abstract][Full Text] [Related]
7. Current status and advances to improving drug delivery in diffuse intrinsic pontine glioma. Arms LM; Duchatel RJ; Jackson ER; Sobrinho PG; Dun MD; Hua S J Control Release; 2024 Jun; 370():835-865. PubMed ID: 38744345 [TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma. Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423 [TBL] [Abstract][Full Text] [Related]
9. Real-time drug testing of paediatric diffuse midline glioma to support clinical decision making: The Zurich DIPG/DMG centre experience. Mueller T; Laternser S; Guerreiro Stücklin AS; Gerber NU; Mourabit S; Rizo M; Rushing EJ; Kottke R; Grotzer M; Krayenbühl N; Nazarian J; Mueller S Eur J Cancer; 2023 Jan; 178():171-179. PubMed ID: 36455411 [TBL] [Abstract][Full Text] [Related]
10. Functionalized Macrophage Exosomes with Panobinostat and PPM1D-siRNA for Diffuse Intrinsic Pontine Gliomas Therapy. Shan S; Chen J; Sun Y; Wang Y; Xia B; Tan H; Pan C; Gu G; Zhong J; Qing G; Zhang Y; Wang J; Wang Y; Wang Y; Zuo P; Xu C; Li F; Guo W; Xu L; Chen M; Fan Y; Zhang L; Liang XJ Adv Sci (Weinh); 2022 Jul; 9(21):e2200353. PubMed ID: 35585670 [TBL] [Abstract][Full Text] [Related]
11. Diffuse intrinsic pontine glioma (DIPG): A review of current and emerging treatment strategies. Weisbrod LJ; Thiraviyam A; Vengoji R; Shonka N; Jain M; Ho W; Batra SK; Salehi A Cancer Lett; 2024 May; 590():216876. PubMed ID: 38609002 [TBL] [Abstract][Full Text] [Related]
12. The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma. Miyahara H; Yadavilli S; Natsumeda M; Rubens JA; Rodgers L; Kambhampati M; Taylor IC; Kaur H; Asnaghi L; Eberhart CG; Warren KE; Nazarian J; Raabe EH Cancer Lett; 2017 Aug; 400():110-116. PubMed ID: 28450157 [TBL] [Abstract][Full Text] [Related]
13. MELK Inhibition in Diffuse Intrinsic Pontine Glioma. Meel MH; de Gooijer MC; Guillén Navarro M; Waranecki P; Breur M; Buil LCM; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso A; Bugiani M; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E Clin Cancer Res; 2018 Nov; 24(22):5645-5657. PubMed ID: 30061363 [No Abstract] [Full Text] [Related]
14. Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201. Xin DE; Liao Y; Rao R; Ogurek S; Sengupta S; Xin M; Bayat AE; Seibel WL; Graham RT; Koschmann C; Lu QR Neuro Oncol; 2024 Apr; 26(4):735-748. PubMed ID: 38011799 [TBL] [Abstract][Full Text] [Related]
15. A kinome-wide shRNA screen uncovers vaccinia-related kinase 3 (VRK3) as an essential gene for diffuse intrinsic pontine glioma survival. Silva-Evangelista C; Barret E; Ménez V; Merlevede J; Kergrohen T; Saccasyn A; Oberlin E; Puget S; Beccaria K; Grill J; Castel D; Debily MA Oncogene; 2019 Sep; 38(38):6479-6490. PubMed ID: 31324890 [TBL] [Abstract][Full Text] [Related]
16. Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma. Nagaraja S; Vitanza NA; Woo PJ; Taylor KR; Liu F; Zhang L; Li M; Meng W; Ponnuswami A; Sun W; Ma J; Hulleman E; Swigut T; Wysocka J; Tang Y; Monje M Cancer Cell; 2017 May; 31(5):635-652.e6. PubMed ID: 28434841 [TBL] [Abstract][Full Text] [Related]
17. Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047). Monje M; Cooney T; Glod J; Huang J; Peer CJ; Faury D; Baxter P; Kramer K; Lenzen A; Robison NJ; Kilburn L; Vinitsky A; Figg WD; Jabado N; Fouladi M; Fangusaro J; Onar-Thomas A; Dunkel IJ; Warren KE Neuro Oncol; 2023 Dec; 25(12):2262-2272. PubMed ID: 37526549 [TBL] [Abstract][Full Text] [Related]
18. Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma. Meel MH; de Gooijer MC; Metselaar DS; Sewing ACP; Zwaan K; Waranecki P; Breur M; Buil LCM; Lagerweij T; Wedekind LE; Twisk JWR; Koster J; Hashizume R; Raabe EH; Montero Carcaboso Á; Bugiani M; Phoenix TN; van Tellingen O; van Vuurden DG; Kaspers GJL; Hulleman E Clin Cancer Res; 2020 Jul; 26(13):3319-3332. PubMed ID: 32165429 [TBL] [Abstract][Full Text] [Related]
19. Targeting DNA Repair and Survival Signaling in Diffuse Intrinsic Pontine Gliomas to Prevent Tumor Recurrence. Sharma M; Barravecchia I; Teis R; Cruz J; Mumby R; Ziemke EK; Espinoza CE; Krishnamoorthy V; Magnuson B; Ljungman M; Koschmann C; Chandra J; Whitehead CE; Sebolt-Leopold JS; Galban S Mol Cancer Ther; 2024 Jan; 23(1):24-34. PubMed ID: 37723046 [TBL] [Abstract][Full Text] [Related]
20. Signal Transduction in Diffuse Intrinsic Pontine Glioma. Duchatel RJ; Jackson ER; Alvaro F; Nixon B; Hondermarck H; Dun MD Proteomics; 2019 Nov; 19(21-22):e1800479. PubMed ID: 31328874 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]